AI
NMRA icon

Alphabet Inc’s Neumora Therapeutics NMRA Stock Holding History

Alphabet Inc’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-404,732
Closed -$6.9M – 43
2023
Q4 		$6.9M Buy
404,732
+205,124
+103% +$2.52M 0.32% 22
2023
Q3 		$2.82M Buy
+199,608
New +$2.49M 0.18% 26

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alphabet Inc's NMRA Position: Q1 2024 in Review

Alphabet Inc sold out of Neumora Therapeutics (NMRA) in Q1 2024, closing a stake of 404,732 shares — an estimated $6.9M sold.

Alphabet Inc first reported a position in NMRA in Q3 2023 and held it in 2 quarters. The position peaked at $6.9M in Q4 2023. 88 funds tracked by Wall St. Rank hold NMRA as of Q1 2024.

  • Alphabet Inc reported no remaining Neumora Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Alphabet Inc sold 404,732 Neumora Therapeutics shares in Q1 2024, an estimated $6.9M.
  • Alphabet Inc first reported a position in Neumora Therapeutics in Q3 2023 and held it in 2 quarters.
  • Alphabet Inc's Neumora Therapeutics position peaked at $6.9M in Q4 2023.
  • 88 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2024.

Based on Alphabet Inc's 13F filing for Q1 2024, filed 3 May 2024.